From palliation to targeted therapy in myelofibrosis.
Vannucchi
Alessandro M
AM
D016207:Cytokines / Q000097:blood; D006801:Humans; D007249:Inflammation / Q000150:complications; D053613:Janus Kinase 1 / Q000037:antagonists & inhibitors*; D053614:Janus Kinase 2 / Q000037:antagonists & inhibitors* / Q000235:genetics; D009570:Nitriles; D055728:Primary Myelofibrosis / Q000188:drug therapy*; D011720:Pyrazoles / Q000627:therapeutic use*; D011743:Pyrimidines
D016207:Cytokines; D009570:Nitriles; D011720:Pyrazoles; D011743:Pyrimidines; C540383:ruxolitinib; D053613:Janus Kinase 1; D053614:Janus Kinase 2